Omnicell Valuation
Is OMCL * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OMCL * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OMCL * (MX$886) is trading above our estimate of fair value (MX$823.77)
Significantly Below Fair Value: OMCL * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OMCL *?
Key metric: As OMCL * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OMCL *'s PS Ratio? | |
|---|---|
| PS Ratio | 2x |
| Sales | US$1.06b |
| Market Cap | US$2.13b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 81.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OMCL *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.3x | ||
NVCR NovoCure | 3.3x | 9.4% | US$2.0b |
NUVA NuVasive | 1.7x | 6.7% | US$2.1b |
EMBLA Embla Medical hf | 2.6x | 8.5% | DKK 15.4b |
6849 Nihon Kohden | 1.6x | 4.1% | JP¥355.1b |
OMCL * Omnicell | 2x | 6.0% | Mex$2.1b |
Price-To-Sales vs Peers: OMCL * is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (2.6x).
Price to Sales Ratio vs Industry
How does OMCL *'s PS Ratio compare vs other companies in the Global Medical Equipment Industry?
| 129 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 129 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: OMCL * is good value based on its Price-To-Sales Ratio (2x) compared to the Global Medical Equipment industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is OMCL *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate OMCL *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.